Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convert

SAN DIEGO, Sept. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or

Bank of America Corp DE purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company"), today annou

SAN DIEGO, Sept. 16, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or

Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attribute

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Halozyme Therapeutics, Inc. (HALO) Presents at H.C. Wainwright 28th Annual Global Investment Confere

Halozyme Therapeutics, Inc. (HALO) Presents at Morgan Stanley 24th Annual Global Healthcare Conferen

Unlock your portfolio value by investing in high earnings yield stocks like Ternium, Halozyme, POSCO

These four PEG value stocks combine discounted valuations with strong growth prospects, offering inv

Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ: HA

Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of

Squarepoint Ops LLC cut its holdings in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 40.5% in the s

Institutions have pushed Halozyme Therapeutics, Inc. (HALO) shares up 769% since March 2014.

One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks wit

Halozyme Therapeutics, Inc. (HALO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcr

Four GARP stocks combine discounted PEG ratios with strong growth prospects, offering investors valu

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO)

SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") tod

Halozyme Therapeutics is evolving into a diversified, high-margin royalty platform, reducing relianc

Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperfo

3 health care stocks with high momentum could be overbought. Crinetics Pharmaceuticals (CRNX) has RS

Leerink Partners analyst David Risinger upgrades Halozyme Therapeutics (NASDAQ:HALO) from Market

TD Cowen analyst Brendan Smith maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raise

U.S. stocks rose, Nasdaq Composite up 1%. Natera Inc (NTRA) shares jump 20.5% after strong Q2 result

Citizens analyst Jason N. Butler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outp

Wells Fargo analyst Mohit Bansal maintains Halozyme Therapeutics (NASDAQ:HALO) with a Equal-Weigh

Wall Street analysts changed ratings & price targets for top stocks. Check out all changes inclu

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $2.28 per share which beat the an

Halozyme Therapeutics (NASDAQ:HALO) raises FY2026 Adj EPS guidance from $7.75-$8.25 to $8.65-$9.00 v

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announ

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today confir

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announ

Tech stocks recovered on Wednesday, led by a rally in battered software names, as the Nasdaq 100 jum

Agreement provides Takeda with exclusive access to ENHANZE® drug delivery technology for vedolizumab

Stocks were rising again midday Friday, putting Wall Street on pace for a fifth straight day of gain